Compare Meta Platforms Inc (META) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Neurocrine Biosciences Inc — how do they compare? Meta Platforms Inc trades at $724.45 (market cap $1.84T), while Neurocrine Biosciences Inc trades at $142.61 (market cap $14.36B). The key difference: Meta Platforms Inc is far larger — about 128.1× Neurocrine Biosciences Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Neurocrine Biosciences Inc for 23 Days on average.
| META | NBIX | |
|---|---|---|
Market Cap | $1.84T | $14.36B |
Volume | 15,887,049 | 1,237,180 |
Sector | Media | Health |
52-Week High | $777.59 | $185.50 |
52-Week Low | $525.72 | $123.10 |
Typical Hold Time | 127 Days | 23 Days |
Enterprise Value | $1.86T | $14.37B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $723.54, up 0.31% on the day, with a bullish technical signal from moving averages and support at $714. The company reported strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a $21B deal with CoreWeave, driving positive sentiment.
The outlook is positive with an 80% analyst buy rating and a consensus price target of $781, but risks include ongoing youth addiction lawsuits and high capital expenditures. Revenue is projected to grow to $228.2B in 2026, supporting long-term growth despite near-term legal and competitive pressures.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
